Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Insulin Delivery, Other Jun 02 | 2021ATTD 2021 Key Press Releases (June 2)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i May 28 | 2021ADA 2021 Abstract and Session Titles AvailablePurchase Blast
$599
Posted in: Other May 27 | 2021Teplizumab Adcom: 10-7 Split Vote; Questions Raised on Teplizumab's ApprovabilityPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other May 27 | 2021Medtronic CY Q1 '21 Earnings Update; FDA Accepts IND for Lilly/Dicerna Cardiometabolic Asset; Dario Digital Therapeutics PublicationPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other May 26 | 2021InPen and Guardian 4 Sensor Receive CE Mark; Oramed Ph3 Oral Insulin Update; Adocia Files Patents for Obesity, NASH, and T2DMPurchase Blast
$599
Posted in: Other May 25 | 2021Provention Bio Teplizumab Adcom Pre-read Materials PostedPurchase Blast$599
Posted in: Glucagon, Other May 24 | 2021Xeris to Acquire Strongbridge; NGM Bio Discontinues NASH Program; BI Selects NASH Drug Candidate From DicernaPurchase Blast
$599
Posted in: Other May 20 | 2021SURPASS-4 Data Continue to Impress; Arecor and Lilly PartnershipPurchase Blast$599
Posted in: Glucose Monitoring, Other May 19 | 2021Roche Launches Smartphone-controlled Pump; Metronom Enters CGM JV in China; FDA Draft Guidance on T2DM Glycemic Control Devices; Dario Q1 '21 Earnings Update; New Ascensia BGM Portal; Metacrine Ph2 NASH TrialPurchase Blast
$599
Posted in: Other May 18 | 2021Novartis Post-ACC CV Investor Event Highlights; Inclisiran Expected as Class 2 ReviewPurchase Blast
$599
Posted in: Other May 17 | 2021Novo's Ph2 Ziltivekimab Data @ ACC 2021; Sheldon Koenig Takes Over as Esperion CEO; New T1DM Treatment from NeurodonPurchase Blast
$599
Posted in: SGLT2i May 17 | 2021EMPEROR-Reduced, DAPA-CKD, and Vericiguat Opinions?; May 17-20 CHMP AgendaPurchase Blast
$599
Posted in: Bolus Insulin, Glucagon, Glucose Monitoring, Other May 13 | 2021Senseonics, Xeris, Mannkind, and Bayer Q1 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other May 11 | 2021Lilly Obesity Ph2 GGG Tri-agonist Trial; Novo QW Icodec Ph3 T2DM; Sigilon Q1 '21 Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery May 10 | 2021Bigfoot Unity Receives 510(k) Clearance; Bayer's FIGARO-DKD Meets Primary Endpoint; Viatris Q1 '21 Earnings Update; Novo Insulin Product Samples RecalledPurchase Blast
$599
Posted in: Insulin Delivery, SGLT2i May 06 | 2021Omnipod 5 Delayed; Insulet and Lexicon Q1 '21 Earnings UpdatesPurchase Blast